Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,148 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 35,148 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACHILLION PHARMACEUTICALS INC
Report date January 28, 2020 · Filed January 29, 2020
Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2026-01-25 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2027-01-19 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23 | Direct | 0 |
Reported balance
After 2020-01-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-28 · Disposition to issuer · Disposed 42,000 · Balance 0 F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
F2: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
AveXis, Inc.
Report date May 15, 2018 · Filed May 15, 2018
Section 16 reporting ended · disclosed 2018-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 1
1 source rowRow 1 · 2018-05-15 · Disposition to issuer · Disposed 1,106 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.00 · Expires 2026-02-10 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-05-15 · Disposition to issuer · Disposed 26,496 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.25 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-15 · Disposition to issuer · Disposed 2,454 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $133.80 · Expires 2028-03-13 | Direct | 0 |
Reported balance
After 2018-05-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-15 · Disposition to issuer · Disposed 2,905 · Balance 0 F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash.
F2: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 23:08 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 13,300 | $0.00 Strike: $12.89 | $0.00 |
DisclosureSEC source: 0001545794-26-000001 · ownership.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,300 Underlying: Common Stock · 13,300 shares Expires 2036-06-08 F2 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 23:08 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 9,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001545794-26-000001 · ownership.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,148 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,450 | $0.00 Strike: $8.37 | $0.00 |
DisclosureSEC source: 0000950170-25-086287 · ownership.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,450 Underlying: Common Stock · 11,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: This option was granted on June 11, 2025 with respect to 11,450 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086287 · ownership.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,948 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 21:00 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | SaleCommon Stock | 1,505 | $25.00 | $37,625.00 |
DisclosureSEC source: 0000950170-24-075718 · ownership.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,948 F1 · kind: The reported sale of 1,505 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 7, 2024. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 11,515 | $0.00 Strike: $25.85 | $0.00 |
DisclosureSEC source: 0000950170-24-073704 · ownership.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2034-06-11 F2 · derivative.exercise_date: This option was granted on June 12, 2024 with respect to 11,515 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:22 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-073704 · ownership.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,453 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 6,473 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037898 · doc4.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Common Stock · 6,473 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2023 with respect to 6,473 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:29 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037898 · doc4.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,716 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 7,688 | $0.00 Strike: $38.49 | $0.00 |
DisclosureSEC source: 0001209191-22-037604 · doc4.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,688 Underlying: Common Stock · 7,688 shares Expires 2032-06-13 F2 · derivative.exercise_date: This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 22:46 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 5,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037604 · doc4.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 3,382 | $0.00 Strike: $83.59 | $0.00 |
DisclosureSEC source: 0001209191-21-043385 · doc4.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,382 Underlying: Common Stock · 3,382 shares Expires 2031-06-22 F2 · derivative.exercise_date: This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 22:14 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 2,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043385 · doc4.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094 F1 · security: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 20:47 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $20.72 | $0.00 |
DisclosureSEC source: 0001209191-20-037971 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: This option was granted on June 18, 2020 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:16 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 42,000 | Not disclosed Strike: $2.18 | Not disclosed |
DisclosureSEC source: 0001562180-20-000678 · primarydocument.xml · derivative · entry 4 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:16 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $2.90 | Not disclosed |
DisclosureSEC source: 0001562180-20-000678 · primarydocument.xml · derivative · entry 3 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-02-09 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:16 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $4.09 | Not disclosed |
DisclosureSEC source: 0001562180-20-000678 · primarydocument.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-01-19 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| January 28, 2020 Filed Jan 29, 2020 16:16 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | Disposition to issuerStock Options (Right to buy) · Derivative | 30,000 | Not disclosed Strike: $7.54 | Not disclosed |
DisclosureSEC source: 0001562180-20-000678 · primarydocument.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-01-25 F1 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: On January 28, 2020, Achillion Pharmaceuticals, Inc. ("Achillion") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document |
| May 21, 2019 Filed May 22, 2019 20:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-19-032086 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2019 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:55 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantStock Option (Right to buy) · Derivative | 42,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001209191-19-005384 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests and becomes exercisable in equal quarterly installments over the one-year period following the date of grant. Read SEC document |
| May 17, 2018 Filed May 21, 2018 16:51 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $25.98 | $0.00 |
DisclosureSEC source: 0001209191-18-031688 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option was granted on May 17, 2018 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:42 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-030132 · doc4.xml · derivative · entry 4 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:42 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-18-030132 · doc4.xml · derivative · entry 3 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:42 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,496 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030132 · doc4.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,496 shares Expires 2026-02-10 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding stock option was canceled in exchange for a lump sum cash payment equal the excess of (A) the Offer Price minus (B) the Exercise Price, multiplied by the number of shares of Common Stock underlying the option. Read SEC document |
| May 15, 2018 Filed May 15, 2018 12:42 UTC | AveXis, Inc. AVXS · Entity 166664 | Disposition to issuerCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030132 · doc4.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. F2 · shares: Represents 1,106 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the Merger Agreement, each outstanding RSU was canceled in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On April 6, 2018, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Novartis AG, a company organized under the laws of Switzerland ("Parent"), and Novartis AM Merger Corporation, a Delaware corporation and an indirect wholly-owned subsidiary of the Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $218.00 per share (the "Offer Price") in cash. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 17:51 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,905 | $0.00 Strike: $133.80 | $0.00 |
DisclosureSEC source: 0001209191-18-022240 · doc4.xml · derivative · entry 2 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905 Underlying: Common Stock · 2,905 shares Expires 2028-03-13 F2 · derivative.exercise_date: This option shall vest and become exercisable on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| March 13, 2018 Filed Mar 30, 2018 17:51 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantCommon Stock | 1,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-022240 · doc4.xml · nonDerivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. F1 · price: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares underlying this restricted stock award will vest on March 13, 2019, subject to the Reporting Person's continuous service with the Issuer on such date. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 17:13 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 30,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-18-009651 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-02-09 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter. Read SEC document |
| July 25, 2017 Filed Jul 25, 2017 20:49 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $16.91 | $0.00 |
DisclosureSEC source: 0001209191-17-046194 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2027-07-24 F1 · derivative.exercise_date: This option was granted on July 25, 2017 with respect to 38,000 shares of Common Stock, with 33% vesting on July 25, 2018 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 18:08 UTC | AveXis, Inc. AVXS · Entity 166664 | GrantStock Option (Right to Buy) · Derivative | 2,454 | $0.00 Strike: $69.25 | $0.00 |
DisclosureSEC source: 0001209191-17-036899 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,454 Underlying: Common Stock · 2,454 shares Expires 2027-05-30 F1 · derivative.exercise_date: The option shall vest and become exercisable (i) in twelve equal monthly installments beginning on June 30, 2017, or (ii) on the date of the Issuer's next annual stockholder meeting, whichever comes first, in each case subject to the Reporting Person's Continuous Service (as that term is defined in the Issuer's 2016 Equity Incentive Plan) through each such date. Read SEC document |
| January 19, 2017 Filed Jan 19, 2017 17:28 UTC | ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234 | GrantEmployee Stock Option · Derivative | 30,000 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001209191-17-004622 · doc4.xml · derivative · entry 1 Verwiel Frank · CIK 0001545794 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option vests as to 25% of the original number of shares on the date of grant and as to an additional 2.08% of the original number of shares at the end of each monthly period thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.